News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
284,524 Results
Type
Article (15515)
Company Profile (285)
Press Release (268724)
Section
Business (84747)
Career Advice (195)
Deals (14779)
Drug Delivery (37)
Drug Development (51816)
Employer Resources (31)
FDA (6237)
Job Trends (5419)
News (153711)
Policy (11036)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (4)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (6)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (932)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (22944)
ALS (54)
Alzheimer's disease (809)
Antibody-drug conjugate (ADC) (79)
Approvals (6248)
Artificial intelligence (100)
Autoimmune disease (7)
Automation (5)
Bankruptcy (115)
Best Places to Work (4629)
BIOSECURE Act (7)
Biosimilars (35)
Biotechnology (234)
Bladder cancer (40)
Brain cancer (19)
Breast cancer (133)
Cancer (1193)
Cardiovascular disease (94)
Career advice (168)
Career pathing (2)
CAR-T (102)
Cell therapy (293)
Cervical cancer (5)
Clinical research (41907)
Collaboration (471)
Compensation (202)
Complete response letters (13)
COVID-19 (1039)
CRISPR (33)
C-suite (132)
Cystic fibrosis (75)
Data (1240)
Denatured (11)
Depression (29)
Diabetes (120)
Diagnostics (1434)
Digital health (5)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (74)
Drug pricing (27)
Drug shortages (3)
Duchenne muscular dystrophy (64)
Earnings (31680)
Editorial (16)
Employer branding (4)
Employer resources (29)
Events (49791)
Executive appointments (392)
FDA (6807)
Featured Employer (35)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (435)
Gene editing (80)
Generative AI (9)
Gene therapy (212)
GLP-1 (345)
Government (1107)
Grass and pollen (2)
Guidances (18)
Healthcare (6857)
Huntington's disease (22)
IgA nephropathy (18)
Immunology and inflammation (71)
Indications (17)
Infectious disease (1096)
Inflammatory bowel disease (109)
Inflation Reduction Act (8)
Influenza (16)
Intellectual property (51)
Interviews (31)
IPO (7651)
IRA (11)
Job creations (1087)
Job search strategy (151)
Kidney cancer (6)
Labor market (4)
Layoffs (201)
Leadership (2)
Legal (1807)
Liver cancer (30)
Lung cancer (170)
Lymphoma (77)
Machine learning (1)
Management (7)
Manufacturing (112)
MASH (47)
Medical device (2929)
Medtech (2930)
Mergers & acquisitions (7382)
Metabolic disorders (344)
Multiple sclerosis (46)
NASH (13)
Neurodegenerative disease (53)
Neuropsychiatric disorders (22)
Neuroscience (1150)
NextGen: Class of 2025 (2065)
Non-profit (887)
Northern California (1425)
Now hiring (22)
Obesity (174)
Opinion (103)
Ovarian cancer (51)
Pain (38)
Pancreatic cancer (48)
Parkinson's disease (95)
Partnered (6)
Patents (100)
Patient recruitment (57)
Peanut (35)
People (26944)
Pharmaceutical (50)
Pharmacy benefit managers (5)
Phase I (14585)
Phase II (19331)
Phase III (12491)
Pipeline (589)
Podcasts (42)
Policy (35)
Postmarket research (1032)
Preclinical (6094)
Press Release (31)
Prostate cancer (50)
Psychedelics (35)
Radiopharmaceuticals (210)
Rare diseases (263)
Real estate (1537)
Recruiting (12)
Regulatory (9066)
Reports (15)
Research institute (952)
Resumes & cover letters (21)
Rett syndrome (3)
RNA editing (1)
RSV (12)
Schizophrenia (52)
Series A (86)
Series B (51)
Service/supplier (1)
Sickle cell disease (37)
Southern California (1260)
Special edition (10)
Sponsored (11)
Startups (2031)
State (1)
Stomach cancer (4)
Supply chain (18)
The Weekly (31)
United States (11402)
Vaccines (202)
Venture capitalists (27)
Webinars (7)
Weight loss (97)
Women's health (14)
Worklife (2)
Date
Last 7 days (407)
Last 30 days (1604)
Last 365 days (20698)
2025 (3609)
2024 (21101)
2023 (23088)
2022 (28658)
2021 (29488)
2020 (24804)
2019 (17145)
2018 (12451)
2017 (14746)
2016 (12871)
2015 (15841)
2014 (11498)
2013 (8272)
2012 (8331)
2011 (8353)
2010 (8134)
Location
Africa (162)
Alabama (37)
Alaska (2)
Arizona (51)
Arkansas (6)
Asia (17671)
Australia (2998)
California (3248)
Canada (1005)
China (293)
Colorado (126)
Connecticut (136)
Delaware (81)
Europe (47029)
Florida (379)
Georgia (95)
Idaho (16)
Illinois (205)
India (8)
Indiana (81)
Iowa (2)
Japan (65)
Kansas (60)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (428)
Massachusetts (2628)
Michigan (68)
Minnesota (130)
Mississippi (1)
Missouri (23)
Montana (14)
Nebraska (5)
Nevada (14)
New Hampshire (13)
New Jersey (829)
New Mexico (11)
New York (906)
North Carolina (534)
North Dakota (4)
Northern California (1425)
Ohio (104)
Oklahoma (8)
Oregon (21)
Pennsylvania (617)
Puerto Rico (1)
Rhode Island (13)
South America (232)
South Carolina (3)
Southern California (1260)
Tennessee (24)
Texas (366)
Utah (45)
Virginia (73)
Washington D.C. (27)
Washington State (309)
Wisconsin (14)
284,524 Results for "silence therapeutics plc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cardiovascular disease
Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner
The search for a partner for zerlasiran is ongoing, according to Silence. In the meantime, the biotech will focus its resources on divesiran, which it is testing for polycythemia vera and other hematologic indications.
February 28, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
March 5, 2025
·
1 min read
Silence Therapeutics to Present at Jefferies Global Healthcare Conference
Silence Therapeutics plc today announced the Company will present at the Jefferies Global Healthcare Conference on Thursday, June 6th at 2:30 p.m. ET.
May 30, 2024
·
1 min read
Press Releases
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
February 27, 2025
·
10 min read
Business
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
Silence Therapeutics plc today announced that Alistair Gray, who has served as an independent member of Silence’s Board of Directors (the “Board”) since 2015, informed the Company that he will retire from the Board, effective May 1, 2024.
April 29, 2024
·
2 min read
Press Releases
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
February 14, 2025
·
1 min read
Business
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
Silence Therapeutics plc, today reported its financial results for the first quarter ended March 31, 2024 and reviewed recent business highlights.
May 16, 2024
·
7 min read
Business
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
Silence Therapeutics plc today announced that it will receive a $2.0 million cash payment from Hansoh Pharmaceutical Group Company Limited (“Hansoh”) following the achievement of a second undisclosed milestone related to the first target under the collaboration.
June 24, 2024
·
5 min read
Drug Development
Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients
Silence Therapeutics plc announced positive results from the ongoing SANRECO Phase 1 repeat dose study of divesiran, a siRNA targeting TMPRSS6, in patients with polycythemia vera.
June 27, 2024
·
9 min read
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
Silence Therapeutics plc today announced the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference.
April 30, 2024
·
1 min read
1 of 28,453
Next
